{
    "nct_id": "NCT05856331",
    "official_title": "Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema",
    "inclusion_criteria": "1. Males or females 18-80 years of age, inclusive, at the time of screening\n2. Diagnosis of AATD\n3. Evidence of emphysema secondary to AATD\n4. FEV1 of ≥ 30% and ≤ 80% predicted at screening\n5. Current non-smoking status.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "1. Receipt of A1PI augmentation therapy within 5 weeks prior to the first dose of study drug\n2. Known or suspected allergy to components of SAR447537 (INBRX-101), A1PI or human IgG\n3. Known selective or severe Immunoglobulin A (IgA) deficiency\n4. Known or suspected diagnosis of type 1 diabetes or diagnosed with uncontrolled type 2 diabetes\n5. Received IV immunoglobulins, monoclonal antibodies and/or other biologic therapies within 30 days\n6. On waiting list for lung or liver transplant\n7. Acute respiratory tract infection or COPD exacerbation within 4 weeks prior to or during screening\n8. Evidence of decompensated cirrhosis\n9. Active cancers or has a history of malignancy within 5 years prior to screening\n10. History of unstable cor pulmonale\n11. Clinically significant congestive heart failure",
    "miscellaneous_criteria": ""
}